"Mercaptopurine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
| Descriptor ID |
D015122
|
| MeSH Number(s) |
D02.886.489.534 D03.633.100.759.534
|
| Concept/Terms |
Mercaptopurine- Mercaptopurine
- 6-Thiopurine
- 6 Thiopurine
- 6-Mercaptopurine Monohydrate
- 6 Mercaptopurine Monohydrate
- 1,7-Dihydro-6H-purine-6-thione
- 6-Thiohypoxanthine
- 6 Thiohypoxanthine
|
Below are MeSH descriptors whose meaning is more general than "Mercaptopurine".
Below are MeSH descriptors whose meaning is more specific than "Mercaptopurine".
This graph shows the total number of publications written about "Mercaptopurine" by people in this website by year, and whether "Mercaptopurine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 2 | 2 | 4 |
| 2019 | 0 | 2 | 2 |
| 2022 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mercaptopurine" by people in Profiles.
-
Sinusoidal Obstruction Syndrome of the Liver Associated With 6-Mercaptopurine During Maintenance in a Child With T-cell Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2023 01 01; 45(1):e121-e123.
-
Use of allopurinol to reduce hepatotoxicity from 6-mercaptopurine (6-MP) in patients with acute lymphoblastic leukemia (ALL). Leuk Lymphoma. 2020 05; 61(5):1246-1249.
-
50 Years Ago in The Journal of Pediatrics: Prevention and Management of Acute Hyperuricemia in Childhood Leukemia. J Pediatr. 2017 12; 191:178.
-
Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8.
-
Use of allopurinol in children with acute lymphoblastic leukemia to reduce skewed thiopurine metabolism. Pediatr Blood Cancer. 2014 Jun; 61(6):1114-7.
-
Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit. Aliment Pharmacol Ther. 2012 Dec; 36(11-12):1049-56.
-
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18; 113(25):6330-7.
-
Does intravenous 6-mercaptopurine decrease salvage after relapse in childhood acute lymphoblastic leukemia? Pediatr Blood Cancer. 2006 May 01; 46(5):660-1.
-
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002 Jul; 26(7):643-9.
-
Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation. J Pediatr Hematol Oncol. 2001 Dec; 23(9):629-32.